🔗 Share this article

As the US undertakes historic revisions to its vaccination recommendations, one figure has emerged somewhat surprisingly: Høeg, a US-based physician and public health researcher who first made her name by questioning Covid vaccines in the global health crisis and has concentrated on possible deaths after Covid immunization in her short tenure at the FDA.

Proposed Shifts to Childhood Immunization Schedule

Agency leaders planned to announce radical revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish national calendar, it is understood – a significant shift that would put the US out of alignment with a large portion of the international standard with little proof for improved outcomes. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Høeg is listed to speak at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to run the office this year.

A New Direction at the Agency

This interim role could signify a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

The new acting director has often pushed for ending certain pediatric shot schedules in the US to become more like the Danish model, a society with nationalized medicine and a citizenry about the population of Wisconsin’s.

So far statements, she has continued to focus on vaccines – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Qualifications

The appointee has no apparent background in drug development, oversight or leadership, which has been standard for previous leaders of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the CDER, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She has no expertise in industry regulation.”

Past commissioners of the center would “grasp laws and regulations and the research of medication creation”, commented a former acting FDA commissioner. “Frankly, she lacks the sort of resume that former directors who led CBER have had.”

The drug center has an vast workload at the FDA, the former commissioner stated.

“The public just pays attention on the innovative therapies, but the off-patent medication office clears a multitude of generic drugs. There is also a biosimilars program, OTC medication office and so forth, and every single one have to be supervised,” she noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a major leadership element to the job, which supervises in excess of 5,000 employees. “It is a enormous management job, if you perform it correctly,” Woodcock said.

Official Statement and Controversial Programs

Regarding inquiries about Høeg’s qualifications and whether this assignment represents increased cooperation among regulatory chiefs on immunizations, a representative responded that the “concerns are based on inaccurate premises”.

“This background is consistent with the functions of her position,” the official stated, pointing to the time Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg takes over the commissioner’s new fast-track approval initiative, a disputed expedited therapy clearance system that apparently worried her preceding directors. “By what process are these drugs being chosen for this voucher program? Who takes the calls?” Howard said. “There is a lot of confidentiality happening at the regulatory body right now.”

In general, he remarked, “the agency looks to be trending towards laxer oversight of most medications, aside from immunizations.”

Established History on Vaccines

Concerning immunizations, Høeg has a clearer, if concerning, track record, critics observe. She authored a research paper using non-validated crowd-sourced reports to estimate the rate of myocarditis following Covid immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccines are riskier than they are.

Included in her “desired changes” for the incoming federal leadership featured changing rules for novel immunizations and ending “unnecessary” vaccines, she said following the vote on a audio program. At the FDA, Dr. Høeg has reportedly proposed preventing teenage boys from obtaining COVID-19 vaccines.

“She is an all-around true believer who starts off with her conclusions and works backwards to accommodate the data in a very misleading, dishonest manner,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow contrarians, {like|